Minority Predoctoral Fellowship Program
少数族裔博士前奖学金计划
基本信息
- 批准号:7485839
- 负责人:
- 金额:$ 5.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-03-09 至 2009-08-14
- 项目状态:已结题
- 来源:
- 关键词:AddressAdrenergic AgentsAffectAmino AcidsCa(2+)-Calmodulin Dependent Protein KinaseCardiacCardiovascular PhysiologyCardiovascular systemClinicalComplexDecompression SicknessDiseaseExhibitsFamilial Hypertrophic CardiomyopathyFellowshipFellowship ProgramHeartHeart failureHomeostasisHumanHypertrophyIn VitroIndividualInvestigationKineticsLeadLinkMeasuresMechanicsMethodologyMinorityModelingMotionMusMuscle CellsMutationMyocardiumMyopathyN-terminalNamesOrganPathogenesisPatternPeptidesPhenotypePhosphorylationPhysiologicalPhysiologyPliabilityPropertyProteinsRegulationRoleSERCA2aSeveritiesSignal PathwaySignal TransductionStagingStructureSudden DeathTailTestingTherapeutic InterventionThin FilamentTimeTransfectionTransgenic MiceTroponinTroponin TVentricularWorkadrenergiccell motilitygenetic regulatory proteinmolecular dynamicsmutantnovel therapeuticsphospholambanpre-doctoralprotein protein interactionresponseuptake
项目摘要
DESCRIPTION (provided by applicant): Mutations in cardiac thin filament regulatory protein, Troponin T, have recently been linked to Familial Hypertrophic Cardiomyopathy, a cause of sudden death in young people. The severity of the disorder is not related to the degree of hypertrophy and is more likely to be due to alterations in cardiovascular physiology at the cellular level. Prior work in the lab has established that varied phenotypes at the whole-organ level are determined by distinct mutation-specific alterations in the thin filament. Specifically, altered flexibility in the N- terminal portion of TnT affects thin filament function and alters downstream myocellular signaling pathways. Changes in Ca2+ kinetics also contribute to pathogenesis. It can be hypothesized that cTnT mutations undergo mechanisms in which thin-filament protein interactions may be disrupted due to changes in flexibility resulting in altered physiologic signaling, which drives distinct phenotypes. The changes in flexibility of cTnT and its effects on thin filament function will be investigated. Changes in mechanics and Ca2+ homeostasis in cTnT mutation (Arg92Trp) will be characterized, which are a result of affected myocellular signaling pathways (beta-adrenergic and calmodulin kinase II activity) and temporal patterns also under investigation.
描述(由申请人提供):心脏细丝调节蛋白肌钙蛋白T的突变最近与家族性肥厚性心肌病有关,这是年轻人猝死的一个原因。该疾病的严重程度与肥大程度无关,更可能是由于细胞水平上的心血管生理学改变。实验室先前的工作已经确定,在整个器官水平上的不同表型是由细丝中不同的突变特异性改变决定的。具体而言,TnT的N-末端部分的柔性改变影响细丝功能并改变下游肌细胞信号传导途径。Ca 2+动力学的变化也有助于发病机制。可以假设cTnT突变经历了这样的机制,其中细丝蛋白相互作用可能由于柔性的变化而被破坏,从而导致改变的生理信号传导,这驱动了不同的表型。将研究cTnT柔性的变化及其对细丝功能的影响。将描述cTnT突变(Arg 92 Trp)中力学和Ca 2+稳态的变化,这是受影响的肌细胞信号传导途径(β-肾上腺素能和钙调蛋白激酶II活性)和时间模式的结果,也正在研究中。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Guinto J Pia其他文献
Guinto J Pia的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8358448 - 财政年份:2012
- 资助金额:
$ 5.86万 - 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8517552 - 财政年份:2012
- 资助金额:
$ 5.86万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7952159 - 财政年份:2009
- 资助金额:
$ 5.86万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7952152 - 财政年份:2009
- 资助金额:
$ 5.86万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7719194 - 财政年份:2008
- 资助金额:
$ 5.86万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7605416 - 财政年份:2007
- 资助金额:
$ 5.86万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7605425 - 财政年份:2007
- 资助金额:
$ 5.86万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7378753 - 财政年份:2006
- 资助金额:
$ 5.86万 - 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
- 批准号:
6825160 - 财政年份:2004
- 资助金额:
$ 5.86万 - 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
- 批准号:
2702283 - 财政年份:1997
- 资助金额:
$ 5.86万 - 项目类别:














{{item.name}}会员




